Sandu Pharmaceuticals Limited (BOM:524703)
India · Delayed Price · Currency is INR 38.22
+0.10 (0.26%)
At close: Sep 4, 2026
Sandu Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 696.24 | 699.35 | 671.92 | 672.81 | 653.49 | 655.01 |
| 696.24 | 699.35 | 671.92 | 672.81 | 653.49 | 655.01 | |
Revenue Growth | 4.16% | 4.08% | -0.13% | 2.96% | -0.23% | 11.48% |
Cost of Revenue | 292.79 | 336.25 | 342.36 | 346.4 | 332.83 | 378.31 |
Gross Profit | 403.46 | 363.1 | 329.57 | 326.41 | 320.66 | 276.7 |
Selling, General & Admin | 108.22 | 202.31 | 181.46 | 177.89 | 169.74 | 138.63 |
Other Operating Expenses | 265.12 | 130.78 | 120.49 | 125.57 | 126.05 | 109.33 |
Operating Expenses | 379.97 | 339.87 | 308.65 | 309.29 | 300.97 | 253.26 |
Operating Income | 23.49 | 23.23 | 20.92 | 17.12 | 19.69 | 23.44 |
Interest Expense | -1.16 | -1.08 | -0.95 | -0.54 | -0.72 | -0.74 |
Interest & Investment Income | - | 4.45 | 1.68 | 4.21 | 3.27 | 0.83 |
Other Non Operating Income (Expenses) | 4.44 | -0.04 | -0.08 | -0.06 | -0.08 | -0.36 |
EBT Excluding Unusual Items | 26.77 | 26.56 | 21.56 | 20.73 | 22.17 | 23.17 |
Pretax Income | 26.77 | 26.56 | 21.56 | 20.73 | 22.17 | 23.17 |
Income Tax Expense | 9.06 | 8.89 | 6.07 | 6.12 | 6.96 | 7.27 |
Net Income | 17.71 | 17.66 | 15.49 | 14.61 | 15.21 | 15.89 |
Net Income to Common | 17.71 | 17.66 | 15.49 | 14.61 | 15.21 | 15.89 |
Net Income Growth | 10.13% | 14.03% | 6.00% | -3.90% | -4.33% | 45.47% |
Shares Outstanding (Basic) | 9 | 10 | 10 | 10 | 9 | 8 |
Shares Outstanding (Diluted) | 9 | 10 | 10 | 10 | 9 | 9 |
Shares Change | -9.36% | - | - | 2.42% | 10.93% | 20.08% |
EPS (Basic) | 2.02 | 1.83 | 1.60 | 1.51 | 1.73 | 1.99 |
EPS (Diluted) | 2.02 | 1.83 | 1.60 | 1.51 | 1.61 | 1.87 |
EPS Growth | 21.50% | 14.26% | 5.96% | -6.21% | -13.90% | 21.43% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 53.96 | 0.12 | -6.65 | -8.48 | 1.08 |
Free Cash Flow Per Share | - | 5.58 | 0.01 | -0.69 | -0.90 | 0.13 |
Dividend Per Share | - | 1.000 | 0.800 | 0.800 | 0.750 | 0.750 |
Dividend Growth | - | 25.00% | 0% | 6.67% | 0% | 50.00% |
Gross Margin | 57.95% | 51.92% | 49.05% | 48.51% | 49.07% | 42.24% |
Operating Margin | 3.37% | 3.32% | 3.11% | 2.54% | 3.01% | 3.58% |
Profit Margin | 2.54% | 2.53% | 2.31% | 2.17% | 2.33% | 2.43% |
Free Cash Flow Margin | - | 7.71% | 0.02% | -0.99% | -1.30% | 0.16% |
EBITDA | 30.83 | 27.65 | 25.38 | 21.3 | 23.23 | 26.95 |
EBITDA Margin | 4.43% | 3.95% | 3.78% | 3.17% | 3.55% | 4.11% |
D&A For EBITDA | 7.35 | 4.42 | 4.46 | 4.18 | 3.54 | 3.51 |
EBIT | 23.49 | 23.23 | 20.92 | 17.12 | 19.69 | 23.44 |
EBIT Margin | 3.37% | 3.32% | 3.11% | 2.54% | 3.01% | 3.58% |
Effective Tax Rate | 33.85% | 33.49% | 28.15% | 29.51% | 31.41% | 31.39% |
Revenue as Reported | 700.68 | 703.79 | 673.6 | 677.04 | 656.76 | 655.83 |
Advertising Expenses | - | 92.46 | 69.92 | 74.72 | 56.56 | 47.39 |